RESULTS	However , considerable uncertainty around the ICERs was demonstrated by insulin glargine having a 50 % probability of being cost effective at a willingness-to-pay threshold of $ Can 10,000 per QALY , and a 54 % probability at a $ Can 20,000 threshold .\